rawfin.tv
Skye Bioscience Receives Nasdaq Listing Deficiency Notice
RegulationstocksAI Generated

Skye Bioscience Receives Nasdaq Listing Deficiency Notice

By rawfin.tv Markets Desk||Updated |1 min read|AI-assisted · Methodology

Skye Bioscience (SKYE) has received a deficiency notice from Nasdaq due to its common stock trading below the minimum $1.00 bid price requirement. The notice indicates a compliance issue that the company must address to maintain its listing.

BiotechnologyNasdaq ListingComplianceSmall CapRegulatory

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks